68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks (UROPET)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03604757 |
|
Recruitment Status :
Completed
First Posted : July 27, 2018
Last Update Posted : June 11, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Patients with primary prostate cancer (low, intermediate or high metastatic risk) for whom radical prostatectomy is indicated, will be invited to participate to the present study.
Positron Emission Tomography coupled with scanner (PET-CT) using a radiotracer : 68Ga-RM2 and Positron Emission Tomography coupled with scanner (PET-CT) using another radiotracer : 68Ga-PSMA-617, will be scheduled.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Prostate Cancer | Drug: 68Ga-PSMA-617 PET/CT Drug: 68Ga-RM2 PET/CT | Phase 2 |
Approximately 15% of men with prostate cancer have high-risk disease at diagnosis. For these patients the accuracy of initial staging is of critical importance for treatment decision-making.
Recommended imaging modalities for initial staging include computerized tomography (CT) scan, bone scan, and Magnetic Resonance Imaging (MRI). In addition to initial work-up, 18F-Choline Positron Emission Tomography coupled with scanner (PET-CT) may be proposed in some high-risk patients but its sensitivity for lymph node detection remains limited.
Nowadays, new radiotracers are becoming available for prostate cancer imaging. Among them, PET-CT imaging with radiolabeled ligands of prostate specific membrane antigen (PSMA) could be more sensitive and more specific for the detection of lymph node metastasis in high-risk cancers, as it is the case with radiolabeled PSMA-617 which has demonstrated very promising results in men with metastatic prostate cancer in recent studies.
Therefore, PET imaging with 68Ga-PSMA-617 may participate to optimize work-up in the staging of high-risk patients.
Another family of radiopharmaceuticals aimed to target the Gastrin-Releasing Peptide Receptor (GRP-R) which is overexpressed in low-grade prostatic carcinomas. GRP-R expression is correlated with androgen receptor expression and with better outcomes.
Various radiolabeled GRP analogues have been developed and one of them, 68Ga-RM2, has shown very promising preclinical results. A study in 14 patients with prostate cancer showed encouraging results as related to the detection of primary prostate cancer and metastatic lymph nodes as well as in detection of local recurrence in the prostate bed and nodal relapse. However, 68Ga-RM2 failed to show some bone metastases in hormone-refractory patients. 68Ga-RM2 has also been recently used and compared to 68Ga-PSMA-11 for targeting biochemically recurrent prostate cancer. These radiotracers may offer complementary performances in lymph nodes detection due to their distinct pharmacokinetics.
Since 68Ga-RM2 and 68Ga-PSMA-617 target different cell populations, combining these two radiopharmaceuticals in patients could be of additional value.
The aim of this pilot study is to compare 68Ga-PSMA-617 PET/CT to 68Ga-RM2 PET/CT in 24 patients with prostate cancer of various progression risks to better understand how they could performed a metastatic risk mapping and how they could be used (or combined) in clinical practice.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 22 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Exploratory, Single-institution Study, Comparing 68Ga-RM2 PET/CT Versus 68Ga-PSMA-617 PET/CT in Patients Diagnosed With Prostate Cancer of Various Metastatic Risks Candidates for Radical Prostatectomy - "UROPET" |
| Actual Study Start Date : | April 25, 2018 |
| Actual Primary Completion Date : | December 19, 2019 |
| Actual Study Completion Date : | December 19, 2019 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: PET/CT Imaging |
Drug: 68Ga-PSMA-617 PET/CT
PET/CT Imaging with 68Ga-PSMA-617 injection Drug: 68Ga-RM2 PET/CT PET/CT Imaging with 68Ga-RM2 injection |
- Median Standardized Uptake Value (SUV) [ Time Frame: Day 0 (inclusion) or Day 2 to 21 (Visit 2) ]Median Standardized Uptake Value (SUV) of 68Ga-PSMA-617
- Median Standardized Uptake Value (SUV) [ Time Frame: Day 0 (inclusion) or Day 2 to 21 (Visit 2) ]Median Standardized Uptake Value (SUV) of 68Ga-RM2
- Gleason score [ Time Frame: Day 3 to 60 (Last visit) ]
- Receptor density Bmax [ Time Frame: Day 0 (inclusion) or Day 2 to 21 (Visit 2) ]
- Local radioactive concentration (cpm) [ Time Frame: Day 0 (inclusion) or Day 2 to 21 (Visit 2) ]
- Immunoreactive score (IRS) [ Time Frame: Day 3 to 60 (Last visit) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion criteria :
24 patients divided in :
- 6 patients with low risk prostate cancer (Gleason score ≤ 6 and cT1-T2a and Prostate Specific Antigen (PSA) value < 10 ng/mL)
- 12 patients with intermediate risk prostate cancer (Gleason score 7 or cT2b or PSA value 10-20 ng/mL) divided in : 6 patients who are Gleason score 7(3+4) (favourable intermediate risk) 6 patients who are Gleason score 7(4+3) (unfavourable intermediate risk)
- 6 patients with high risk prostate cancer (Gleason > 7 or cT2c or PSA value > 20 ng/mL)
- Candidate for radical prostatectomy after discussion in multidisciplinary committee
- Covered by the national health insurance system
- Written informed consent willingly obtained
Exclusion criteria :
- any kind of previous treatment for prostate cancer (hormonal treatment, EBRT, brachytherapy, cryotherapy, etc…);
- patient not candidate for radical prostatectomy and/or unable to benefit from surgery
- freedom deprivated patient by judiciary or administrative decision
- patient under legal protection or unable to express its own consent
- patient within exclusion period from another clinical trial
- known contraindication to radiopharmaceuticals and / or excipients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03604757
| France | |
| Bordeaux University Hospital | |
| Bordeaux, France, 33076 | |
| Principal Investigator: | CLERMONT-GALLERANDE Henri | University Hospital, Bordeaux |
| Responsible Party: | University Hospital, Bordeaux |
| ClinicalTrials.gov Identifier: | NCT03604757 |
| Other Study ID Numbers: |
CHUBX 2016/38 |
| First Posted: | July 27, 2018 Key Record Dates |
| Last Update Posted: | June 11, 2020 |
| Last Verified: | June 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Prostate Cancer 68Ga-RM2 bombesin GRP-R |
68Ga-Prostate Specific Membrane Antigen PSMA PET/CT |
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms |
Prostatic Diseases Gallium 68 PSMA-11 Radiopharmaceuticals Molecular Mechanisms of Pharmacological Action |